Nova Mentis Organizes Autism Data Bank in North America
Ryan Allway
April 20th, 2021
Psychedelics
VANCOUVER, BC, April 20, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will be organizing a North American autism spectrum disorder (ASD) data bank to support the Company’s development of psilocybin-based compounds in the diagnosis and treatment of ASD.
This newly launched serotonin research centre, in conjunction with a clinical Institutional Review Board (IRB) approved study, will quantify serotonin levels within various human samples, such as blood, urine and feces. Buccal cheek cells will also be obtained to measure genetic levels of several serotonin transporters.
“The quantitative information collected in the data bank will help to determine onset of ASD, progression of the disorder and response to various treatment modalities,” stated Marvin S. Hausman MD, Chairman of NOVA’s Scientific Advisory Board.
The Company aims to recruit at least 300 participants across the U.S and Canada: 200+ with symptoms suggestive of ASD and 100+ neurotypical controls. Autism patient families will be encouraged to submit samples for analysis. The goal of the study is to identify ASD causative links and to advance personalized treatments through a better understanding of the many subtypes that make up the ‘autism spectrum,’ including fragile X syndrome. The data to be collected will form the basis for the upcoming dosing trial in the U.S., planned for later in 2021.
The study is compliant under the Health Insurance Portability and Accountability Act (HIPAA), which sets the standard for protection of sensitive patient data. Only patients, family, personal physicians, and NOVA scientists will be able to access the data. NOVA has received Institutional Review Board (IRB) approval in the United States for this observational study and is currently organizing Canadian IRB approval.
“Recent scientific data suggests that serotonin plays a dominating role in the development of the nervous system and serotonin levels should be studied in ASD children from birth until five years of age,” added Dr. Hausman. “It is for this reason that NOVA has undertaken the design and launch of a serotonin research centre in the United States. We want to give additional hope for families with autistic children that this unmet medical need is not being forgotten.”
One of the key pillars of NOVA’s research is to increase our understanding of the involvement of the enteric nervous system (ENS) in intestinal and neuroinflammatory conditions, including ASD, and to examine the role serotonin plays in organs outside the brain and in chronic disorders and diseases. Only 5-10 percent of serotonin is produced in the brain, 90-95 percent is produced in the rest of the body, especially in the small intestine. NOVA will be focused on studying the role of serotonin in various parts of the body and how we can use psilocybin to help correct serotonin problems.
The serotonin research centre is a partnership with FourthWall Testing.
Recent scientific statements and articles suggesting the importance of serotonin:
“Serotonin, responsible for mood in the brain and motility in the gut, can also act as a bacterial signaling molecule for pathogenic bacteria.”(1)
A recent University of Maryland School of Medicine study showed in a mouse model that the beneficial effect of psilocybin may work through other mechanisms of action besides a psychedelic experience.(2)
References:
(1) Leslie D. Knecht, Gregory O’Connor, Rahul Mittal, Xue Z. Liu, Pirouz Daftarian, Sapna K. Deo, and Sylvia Daunert. Serotonin Activates Bacterial Quorum Sensing and Enhances the Virulence of Pseudomonas aeruginosa in the Host. EBioMedicine. 2016 Jul; 9: 161–169. Published online 2016 May 28. doi: 10.1016/j.ebiom.2016.05.037.
(2) Natalie Hesselgrave, Timothy A. Troppoli, Andreas B. Wulff, Anthony B. Cole, and Scott M. Thompson. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. PNAS April 27, 2021 118 (17) https://doi.org/10.1073/pnas.2022489118.
About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and Fragile X Syndrome.
For further information on the Company, please visit https://www.novamentis.ca or email info@novamentis.ca.
About FourthWall Testing
A subsidiary of Epitome Risk Solutions, FourthWall Testing is a private lab led by industry experts with more than 70 years of combined experience in drug research and development, as well as risk management services for the entertainment and sporting industries.
For more information, please visit: https://www.epitomerisk.com/fourthwall-testing/
On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
ManifestSeven (M7), formerly known as MJIC, is the first integrated omnichannel platform for legal cannabis, merging compliant distribution with a retail superhighway.
Founded in the spring of 2014, Genius Extraction is owned and operated by its creators, Robert and Brenna Gaither. While Robert brings his sales prowess to the endeavor, Brenna’s strong background, education, and training in biochemistry establish the foundation for the company’s credibility in the extraction industry. With a strong understanding of the extraction industry’s […]
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
